Last updated: August 4, 2025
Introduction
Chinese patent CN110526912 pertains to a novel pharmaceutical invention that addresses specific medical or therapeutic challenges. As China’s intellectual property environment evolves rapidly, understanding the scope, claims, and landscape surrounding this patent offers insights into strategic patent management, competitive positioning, and innovation trends.
Patent Overview
CN110526912 was granted on August 16, 2022, by the China National Intellectual Property Administration (CNIPA). According to the official patent database, the invention relates to a specific drug composition, manufacturing process, or therapeutic use, though detailed claims are necessary to precisely delineate scope.
The inventor(s) is likely affiliated with a Chinese pharmaceutical company or research institution, reflecting ongoing innovation pushes within China's biopharma sector.
Scope of Patent CN110526912
1. Patent Classification and Technical Field
CN110526912 falls within the International Patent Classification (IPC) codes such as A61K (Preparations for medical, dental, or toilet purposes), C07D (Heterocyclic compounds), or other relevant classes depending on the specific molecular or formulation focus. Its classification indicates it belongs to pharmaceutical compositions, synthesis methods, or specific treatment indications.
2. Technical Focus and Objectives
The patent's scope encompasses a new drug compound, a novel formulation, or an innovative method of preparation designed to enhance efficacy, reduce side effects, or improve stability. It may also incorporate a specific therapeutic application, such as cancer, infectious diseases, or metabolic disorders.
3. Geographical and Market Scope
As a Chinese patent, its primary protection is nationally enforceable within China. The scope extends to manufacturing, use, and sale of the patented invention in China. For broader enforceability, patent families might target jurisdictions like PCT applications or national phase filings in key markets such as the U.S., EU, or Japan.
Claims Analysis
1. Types of Claims
The patent includes:
- Independent claims: Define the core inventive concept, often covering the drug compound or process.
- Dependent claims: Elaborate on specific embodiments, such as particular compound variants, dosage forms, or manufacturing steps.
2. Claim Language and Specificity
The claims likely specify the molecular structure, functional groups, or combination of active ingredients. For example, if it involves a new chemical entity, structural formulas are provided, with limitations on substituents and stereochemistry.
The scope of claims tends to balance broadness—covering variations of the molecule or process—and specificity, ensuring infringement can be reasonably detected without undue ambiguity.
3. Novelty and Inventive Step
The claims emphasize distinctions over prior art, focusing on unique structural features or innovative steps absent in existing patents or publications. The inventive step probably hinges on a specific modification that enhances drug stability, bioavailability, or therapeutic index.
4. Scope Limitations
- If the claims are broad, covering generic variations, competitors must design around the patent or challenge its validity.
- Narrow claims may provide limited freedom to operate but could be easier to defend in litigation.
5. Claim Strategy
The patent appears to adopt a multi-tiered claim approach, combining broad claims on the compound or method with narrower claims on specific embodiments, enabling protection of core innovations while maintaining fallback options.
Patent Landscape and Competitive Position
1. Global Patent Family and Priority
It remains essential to analyze whether CN110526912 is part of a broader patent family filed via PCT or in other jurisdictions. Such a family extends protection beyond China, increasing the patent’s strategic value and blocking competitors internationally.
2. Existing Patents and Art
The Chinese patent landscape for pharmaceutical innovations, especially in molecular compounds and formulations, is highly active. Several patent families in China, the U.S., and Europe may target similar therapeutic targets, pathways, or chemical structures, creating a densely crowded landscape.
For example, if the invention relates to kinase inhibitors, it would intersect with a broad body of existing patents. Effective positioning requires demonstrating the novelty over such prior art.
3. Innovation Trends
- Using structural modifications to circumvent existing patents.
- Incorporating delivery system innovations.
- Targeting novel indications or combination therapies.
4. Competitor Analysis
Major Chinese players, such as China National Pharmaceutical Group (Sinopharm), Shanghai Fosun, or innovative startups, could have filed related patents. Patent landscaping tools can identify overlapping applications and potential licensing or litigation risks.
Implications for Industry and Strategy
- Freedom to Operate (FTO): A thorough analysis of claims indicates whether the patent poses barriers for unlicensed development or commercialization of similar compounds.
- Patent Strength: Broad, well-drafted claims with strong inventive step bolster patent enforceability, while overly narrow claims risk circumvention.
- R&D Focus: The scope suggests targeted innovation areas—potentially in novel chemical entities or unique manufacturing methods—steering R&D investments accordingly.
- Legal and Commercial Risks: The densely patentable space in China's pharmaceuticals warrants vigilance for invalidation challenges, especially if prior art searches reveal similar molecules or processes.
Legal and Regulatory Considerations
- CN110526912’s enforceability depends on its adherence to Chinese patent law standards, including clarity, novelty, and inventive step.
- Patent term in China extends 20 years from the filing date, incentivizing timely commercialization.
- Ongoing patent life, patent litigation history, and potential challenges are critical for strategic planning.
Conclusion
Patent CN110526912 exemplifies China's evolving pharmaceutical innovation landscape, with its scope centered on novel chemical compounds or formulations tailored to therapeutic advancements. The claims demonstrate a strategic balance between breadth and specificity, with implications for market exclusivity and competitive positioning.
Business stakeholders should leverage detailed patent landscape analysis to assess freedom to operate, identify licensing opportunities, and inform R&D strategies aligned with China's IP environment.
Key Takeaways
- Scope and Claims: The patent’s core protection likely covers a specific chemical entity or process, with claims crafted to balance broad coverage and enforceability.
- Landscape Considerations: CN110526912 is situated within a competitive and dense patent environment, necessitating detailed landscape mapping to avoid infringement or invalidation risks.
- Strategic Protection: Broader claims that encompass chemical variants and manufacturing steps can fortify market exclusivity, but narrow claims may limit dispute risks.
- International Extension: Filing in other jurisdictions via PCT or direct applications enhances global protection and market potential.
- Ongoing Monitoring: Continuous patent landscape surveillance is critical to adapt to evolving prior art and competitor filings.
FAQs
1. What is the main inventive concept behind CN110526912?
While specific molecular details require direct claim review, the patent is centered on a novel drug compound or formulation with enhanced therapeutic efficacy or stability, distinguishing it from prior art.
2. How does CN110526912 compare to similar international patents?
It may either be part of a broader patent family filed via PCT, or unique to China. Comparative analysis with international patents reveals whether it is strategically embedded in a global innovation effort.
3. What are the potential risks of patent infringement in this space?
Given the crowded landscape, overlapping claims could lead to infringement risks. Competitors may challenge the patent’s validity by citing prior art, particularly if claims are overly broad.
4. Can the patent’s scope be expanded or challenged?
Yes; claiming broader structural variants or manufacturing methods diversifies protection. Conversely, invalidity challenges may target the novelty or inventive step of existing claims.
5. How should innovators utilize this patent data?
By analyzing claim language, inventors can design around existing patents, identify licensing opportunities, or pinpoint areas ripe for breakthrough innovation.
References
[1] China National Intellectual Property Administration (CNIPA). Patent Database. CN110526912.
[2] World Intellectual Property Organization (WIPO). Patent Landscape Reports.
[3] Chinese Patent Law, 2020 Amendment.
[4] Patentability Guidelines, CNIPA.
